JP Morgan Chase
ZNTL icon

JP Morgan Chase’s Zentalis Pharmaceuticals ZNTL Stock Holding History

JP Morgan Chase’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,600
Closed -$121K – 7063
2022
Q3 		$121K Buy
+5,600
New +$153K ﹤0.01% 5205

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

JP Morgan Chase's ZNTL Position: Q1 2026 in Review

JP Morgan Chase reduced its Zentalis Pharmaceuticals (ZNTL) stake by 39% in Q1 2026, selling an estimated $186K and leaving 113,126 shares worth $242K. The position accounts for ﹤0.01% of the portfolio, ranked #5392.

JP Morgan Chase first reported a position in ZNTL in Q2 2020 and has held it in 24 quarters since. The position peaked at $4.87M in Q1 2022. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • JP Morgan Chase held 113,126 shares of Zentalis Pharmaceuticals worth $242K as of Q1 2026.
  • JP Morgan Chase sold 71,881 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $186K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5392 holding.
  • JP Morgan Chase first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • JP Morgan Chase's Zentalis Pharmaceuticals position peaked at $4.87M in Q1 2022.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.